Which is better, APLS or RMD?

On the Buffett-Fit framework, Apellis Pharmaceuticals, Inc. (APLS) currently grades higher than RMD — 58/100 (C grade) vs 72/100 (B). That said, "better" depends on which framework you trust — APLS wins on Benjamin Graham, Peter Lynch, and Joel Greenblatt; RMD wins on Warren Buffett, Philip Fisher, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy APLS or RMD?

This page is an educational comparison, not investment advice. Both APLS and RMD are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is APLS better than RMD for value investing?

On the Buffett-style value-investing framework, APLS currently grades higher — 72/100 vs 58/100, a 14-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between APLS and RMD on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). APLS currently scores 58/100 (C grade); RMD scores 72/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, APLS or RMD?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. APLS and RMD are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, APLS or RMD?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are APLS and RMD both Healthcare stocks?

Yes — both Apellis Pharmaceuticals, Inc. (APLS) and ResMed Inc. (RMD) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this APLS vs RMD comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Apellis Pharmaceuticals

ResMed

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

APLS

Market cap

$5.25B

Sector

Healthcare

RMD

ResMed

Market cap

$30.18B

Sector

Healthcare

Overall winner

Apellis Pharmaceuticals APLS

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	APLS	RMD	Winner
Warren Buffett	58C	72B	RMD
Benjamin Graham	79D	75B	APLS
Philip Fisher	71C	75B	RMD
Peter Lynch	81C	58C	APLS
Joel Greenblatt	63C	47D	APLS
Charlie Munger	67D	69B	RMD
Terry Smith	65B	73B	RMD

Side-by-side metrics

Metric	APLS	RMD
Market cap	$5.25B	$30.18B
P/E (TTM)	38.8x	19.6x
EV/EBIT	96.0x	17.1x
ROIC (TTM)	18.11%	19.63%
Gross margin	90.12%	61.69%
Net margin	12.06%	27.44%
Revenue CAGR 5y	97.06%	12.64%
EPS CAGR 5y	-	30.73%
Debt / Equity	1.1x	0.1x
Dividend yield	0.0%	1.14%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

APLS leads on

Revenue CAGR 5y97.06%vs 12.64%+87%
Gross margin90.12%vs 61.69%+32%

RMD leads on

Dividend yield1.14%vs 0.0%+100%
Debt / Equity0.1xvs 1.1x+89%
Market cap$30.18Bvs $5.25B+83%
EV/EBIT17.1xvs 96.0x+82%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Apellis Pharmaceuticals

ResMed

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like APLS

More like RMD

Related on invest-like

Key terms in this analysis